Trial Profile
Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Pharmacodynamics
- Acronyms PAIR
- 21 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 11 Dec 2015 New trial record